Aim: A previous study has revealed that the albumin/globulin ratio (GAR) before treatment is a predictor of cancer-specific survival in patients with colorectal cancer (CRC). The aim of the present study was to investigate the clinical significance of GAR for prediction of postoperative survival in patients with CRC.
| INTRODUCTION
In Japan, colorectal cancer (CRC) is the second leading cause of cancer-related death, accounting for approximately 50 000 deaths annually. 1 CRC is also the third most common cancer and the fourth leading cause of cancer-related death worldwide.
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The term "biomarker" commonly means a measurable serum protein substance whose concentration reflects the presence or degree of progression of a neoplasm. In the clinical field, prognostic biomarkers are often used for treatment decision-making, because they are known to be useful predictors of outcome in cancer patients. 3 In fact, the neutrophil-to-lymphocyte ratio (NLR), 4 carcinoembryonic antigen (CEA), 5 and carbohydrate antigen 19-9 (CA19-9) 5 have been broadly used as prognostic biomarkers for patients with CRC. In particular, we have previously reported that the C-reactive protein (CRP)-to-albumin ratio (CAR) 6 and the Glasgow Prognostic Score (GPS) 7 are also useful for prediction of postoperative outcome in patients with CRC.
Cancer cells and other cells or tissues at sites of inflammation produce and secrete excessive amounts of inflammatory cytokines.
Interleukin-6 (IL-6) is a typical inflammatory cytokine, and its level is known to be increased in patients with cancer. 8 IL-6 not only induces differentiation of B-lymphocytes into plasma cells to produce immunoglobulins, but also decreases albumin production in the liver. 9 Recently, this mechanism has been the focus of attention in patients with CRC, and the albumin/globulin ratio is reported to be useful for prognostication in such patients. 10 We have also reported that the globulin-to-albumin ratio (GAR) is a useful predictor of postoperative survival in patients with hepatocellular carcinoma (HCC) undergoing potentially curative liver resection. 11 Because the GAR is the ratio of albumin relative to globulin, it is less affected by measurement variability and can be determined as easily as the NLR.
However, the first study of GAR in CRC patients did not determine the ideal cutoff value, and therefore, further refinement of this value would be of potential clinical utility. 10 Using a clinical database at a single institution, this study was conducted to determine whether the preoperative GAR would be useful for prognostication in CRC patients.
| ME TH ODS
A retrospective review was performed using a database of patients who had undergone elective surgery for CRC. The cutoff values for various clinical characteristics were determined using receiver operating characteristic (ROC) curve analyses.
The recommended cutoff values were based on the most prominent point on the ROC curve for "sensitivity" and "1 -specificity,"
respectively. Then, the ideal cutoff values were defined using the Youden index maximum [sensitivity − (1 − specificity)]. 13 The area under the ROC (AUROC) curve was also calculated.
For example, the optimal cutoff value for the GAR corresponded , CEA (>8.7/≤8.7, ng/mL), CA19-9 (>18.5/≤18.5, U/mL), NLR (>2.9/≤2.9), and GAR (>0.83/≤0.83) to select those that were useful for prediction of overall survival (OS). All cutoff values were defined using ROC analyses, except for gender, tumor site, number of tumors, tumor type, and pathology.
Inflammation-based prognostic system consists of not only protein-based system but also blood cell-based system such as NLR and thrombocytosis. Therefore, WBC and platelet are also added to the univariate analysis in the study. Multivariate analysis was performed using the clinical characteristics selected by univariate analysis with a P-value of <0.05.
| Definition of inflammation-based prognostic systems
The GPS was calculated as follows: Patients with both an elevated level of CRP (>1.0 mg/dL) and hypoalbuminemia (albumin <3.5 g/dL)
were allocated a score of 2, and patients showing one or neither of these blood chemistry abnormalities were allocated a score of 1 or 0, respectively.
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The NLR was calculated as follows: NLR = neutrophil ratio (%) (or number of neutrophils)/lymphocyte ratio (%) (or number of lymphocytes). 4 The GAR was calculated as follows: GAR = serum globulin level In addition, most stage II patients undergoing surgery were not considered for postoperative chemotherapy. 
| Statistical analysis
Data are presented as mean ± SD (standard deviation). Differences among the groups were analyzed using the χ 2 test and Mann-Whitney U-test. Hazard ratio (HR) with 95% CI was calculated by univariate or multivariate analysis using the Cox proportional hazards model. Multivariate analysis was performed using clinical characteristics with P < 0.05 selected in the univariate analysis to assess those most closely related to OS.
Kaplan-Meier analysis and log rank test were used to compare the survival curves for the two groups. Deaths prior to 31 December 2014 were included in this analysis.
Statistical analyses were performed using the IBM SPSS statistics version 22.0 software package for Windows (IBM Co., New York, NY, USA) at a significance level of P < 0.05.
| RESULTS
A total of 941 patients were enrolled (male:female = 581:360). There were 473 patients with low GAR (GAR ≤ 0.83) and 468 with high GAR (GAR > 0.83). Table 1 shows the distribution of the categorical clinical background characteristics of the studied patients in the two GAR groups.
There were significant differences between the two groups in age CEA (>8.7/≤8.7, ng/mL), CA19-9 (>18.5/≤18.5, U/mL), NLR (>2.9/ ≤2.9), and GAR (>0.83/≤0.83) were associated with OS (Table 3) .
Multivariate analysis using the above selected clinical characteristics disclosed that GAR (>0.83/≤0.83) was associated with OS (HR, 1.979; 95% CI, 1.321-2.966; P = 0.001) along with CEA (>8.7/≤8.7, ng/mL; HR, 2.319; 95% CI, 1.569-3.428; P < 0.001), CA19-9 (>18.5/ ≤18.5, U/mL; HR, 1.727; 95% CI, 1.178-2.532; P = 0.005), and NLR (>2.9/≤2.9; HR, 2.132; 95% CI, 1.454-3.126; P < 0.001; Table 4 ).
However, the results of AUROC analysis revealed that the GAR had the largest AUROC among these four clinical characteristics as follows: GAR 0.711 > CEA 0.698 > CA19-9 0.676 > NLR 0.635.
The median and maximum follow-up periods for survivors were 559 and 3389 days, respectively, and the mean survival period was 799 ± 769 days (mean ± SD).
There was no significant difference during the observed period between patients with low GAR (≤0.83; 788 ± 733 days) and patients with high GAR (>0.83; 810 ± 805 days; P = 0.505, MannWhitney U-test; Table 2 ).
Although Kaplan-Meier analyses and log rank tests demonstrated that there were no significant differences between the two groups of stages 0, I, II, and III (GAR ≤ 0.8 vs GAR > 0. Figure 1E ). There was a significant difference between patients with low GAR (≤0.83) and patients with high GAR (>0.83) of all stages in OS (P < 0.001).
Patients with high GAR (>0.83) showed poorer OS than those with low GAR (≤0.83; Figure 2 ). 
T A B L E 1 Relationships between the categorical clinical characteristics and GAR in patients with CRC

| DISCUSSION
Advances in laparoscopic surgery and development of novel chemotherapies are improving the treatment of CRC. In recent years, "precision medicine" has also played a crucial role in maximizing the effects of therapy and minimizing side effects in individual patients. In addition to general medical information, it is important to explore the individual genetic backgrounds, physiological condition, and disease state of patients using biomarkers, and such information is effective for selection of appropriate treatment for each patient.
It has been reported that persistent chronic inflammation is involved in cancer development, progression, and metastasis. 25 Therefore, such inflammation is associated with hypermetabolism, weight loss, and anorexia in cancer patients. 26 In fact, acute-phase proteins such as CRP, which is an important marker of systemic inflammatory response (SIR), is induced by inflammatory cytokines. 27 Tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10), and IL-6 are also inflammatory cytokines that are well known to be involved in various types of cancer. 25 Among them, IL-6 is produced by a variety of cells including T cells, B cells, fibroblasts, monocytes, endothelial cells, and mesangial cells. 28 IL-6 is associated with the development and progression of CRC. 29 Recent studies have shown that the IL-6 level is significantly increased in the tumor microenvironment and that tumor proliferation is suppressed by anti-IL-6 receptor antibody. 30 In fact, the transmembrane IL-6 receptor is expressed on the cell surface of hepatocytes. 31 When IL-6 acts on hepatocytes, there is an increase in gene transcription rate of acute-phase proteins such as CRP, and the rate and synthesis of albumin mRNA transcription compensates decreases. 32 Similarly, when IL-6 acts on B cells, it induces their differentiation into plasma cells, which produce antibody and upregulate immunoglobulin production. 7 Previous studies have also shown that the preoperative albumin/ globulin ratio is an independent prognostic factor in CRC patients. 10 Serum proteins are divided into two groups: albumin and globulins.
Serum albumin constitutes approximately 60% of the total protein, 7 being produced in the liver and functioning to maintain osmotic pressure and the transport of various metabolites. Albumin also has an antioxidant effect against carcinogens (e.g., nitrosamines and aflatoxins) by stabilizing cell proliferation and deoxyribonucleic acid (DNA) replication. 33 Laursen et al. 34 have reported that the growth of a human breast cancer cell line was inhibited by albumin. Other researchers have reported that some cancer patients with hypoalbuminemia have shorter OS and higher recurrence rates. 35 On the other hand, globulins are divided into four groups according to their electrophoretic profiles: alpha 1, alpha 2, beta, and gamma globulins.
Among them, gamma globulin, also called immunoglobulin, is an antibody that plays an extremely important role in the immune system F I G U R E 1 A, Relationship between the globulin-to-albumin ratio (GAR) and overall survival (OS) after surgery for stage 0 colorectal cancer (CRC) patients. B, Relationship between the GAR and OS after surgery for stage I CRC patients. C, Relationship between the GAR and OS after surgery for stage II CRC patients. D, Relationship between the GAR and OS after surgery for stage III CRC patients. E, Relationship between the GAR and OS after surgery for stage IV CRC patients against disease. 36 It is known that the globulin level increases with chronic inflammation due to the activity of inflammatory cytokines. 37 Because the serum levels of albumin and globulin are affected by many factors such as stress, liver failure, dehydration, and edema, they also show measurement variability. However, because the GAR is a ratio rather than an absolute value, it is less affected by measurement variability than the serum levels of albumin and globulin separately. In fact, we have reported that even if patients have liver dysfunction, the GAR would be rarely affected by such condition and could predict the postoperative survival of such patients.
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The present multivariate analysis revealed four prognostic biomarkers: GAR, NLR, CEA, and CA19-9. However, CEA and CA19-9 may show normal levels even in patients with advanced cancer. In fact, it has been reported that approximately 73% of CRC patients who underwent surgery had normal preoperative serum CEA levels 38 and 84% had normal CA19-9 levels. 39 On the other hand, GAR is based on protein components and NLR is based on cell components, and they are less likely to reflect tumor characteristics as both are indicators of inflammation and immune status in individual patients. The AUROC of the four biomarkers was 0.771 for GAR, 0.698 for CEA, 0.676 for CA19-9, and 0.635 for NLR, with GAR having the largest AUROC and demonstrating the closest relationship with outcome in patients with CRC. The cutoff value of GAR determined in our department was 0.93 for HCC and 0.83 for CRC. 11 Because it is difficult to define the ideal cutoff value for GAR because of variation of organs, future studies will need to examine the utility of GAR as a prognostic biomarker. The present study showed superiority over the previous one 10 as its sample size was almost 2-fold larger, and the data were examined in terms of cutoff values. In addition, GAR is less expensive to determine than commonly used tumor markers, and can be repeatedly measured, making it not only versatile but also universally applicable.
In conclusion, the GAR can be used as an easy, cheap, objective, and noninvasive biomarker for prognostication of CRC patients undergoing surgery and is useful for prediction of postoperative survival.
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